These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 27354648)

  • 1. Adoptive Chemoimmunotherapy Using Activated αβ T Cells for Stage IV Colorectal Cancer.
    Yoshida Y; Naito M; Yamada T; Aisu N; Daibo K; Mera T; Tanaka T; Naito K; Yasumoto K; Kamigaki T; Goto S; Yamashita Y; Hasegawa S
    Anticancer Res; 2016 Jul; 36(7):3741-6. PubMed ID: 27354648
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Study on the Medical Value of Combination Therapy Involving Adoptive Immunotherapy and Chemotherapy for Stage IV Colorectal Cancer (COMVI Study).
    Yoshida Y; Naito M; Yamada T; Aisu N; Kojima D; Mera T; Tanaka T; Naito K; Yasumoto K; Kamigaki T; Gotoh S; Kodama S; Yamashita Y; Hasegawa S
    Anticancer Res; 2017 Jul; 37(7):3941-3946. PubMed ID: 28668898
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatectomy for Liver Metastases of Colorectal Cancer After Adoptive Chemoimmunotherapy Using Activated αβ T-cells.
    Ishii F; Yoshida Y; Yamauchi Y; Aisu N; Kojima D; Mera T; Kato D; Tanaka T; Naito K; Yasumoto K; Kamigaki T; Goto S; Hamada Y; Nimura S; Kodama S; Hasegawa S
    Anticancer Res; 2017 Jul; 37(7):3933-3939. PubMed ID: 28668897
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bevacizumab plus XELOX as first-line treatment of metastatic colorectal cancer: The OBELIX study.
    Antonuzzo L; Giommoni E; Pastorelli D; Latiano T; Pavese I; Azzarello D; Aieta M; Pastina I; Di Fabio F; Bertolini A; Corsi DC; Mogavero S; Angelini V; Pazzagli M; Di Costanzo F
    World J Gastroenterol; 2015 Jun; 21(23):7281-8. PubMed ID: 26109816
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changes in Immunological Status in Patients With Metastatic Colorectal Cancer Treated With First-line Chemoimmunotherapy.
    Yamada T; Yoshida Y; Maeda T; Yoshimatsu G; Aisu N; Yamashita K; Komono A; Kajitani R; Matsumoto Y; Nagano H; Naito K; Yasumoto K; Takimoto R; Kamigaki T; Goto S; Yoshimura F; Sakata N; Kodama S; Hasegawa S
    Anticancer Res; 2020 Aug; 40(8):4763-4771. PubMed ID: 32727803
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Capecitabine and oxaliplatin (XELOX) as first-line treatment for patients with metastatic colorectal cancer.
    Karacetin D; Yalcin B; Okten B; Ozturk S; Maral O; Incekara O
    J BUON; 2009; 14(4):605-8. PubMed ID: 20148449
    [TBL] [Abstract][Full Text] [Related]  

  • 7. XELOX and bevacizumab followed by single-agent bevacizumab as maintenance therapy as first-line treatment in elderly patients with advanced colorectal cancer: the boxe study.
    Rosati G; Avallone A; Aprile G; Butera A; Reggiardo G; Bilancia D
    Cancer Chemother Pharmacol; 2013 Jan; 71(1):257-64. PubMed ID: 23100174
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multicentre phase II study of XELOX with bevacizumab in late-stage elderly patients with unresectable advanced/recurrent colorectal cancer: an ASCA study.
    Oba K; Matsuoka M; Satoh T; Muro K; Oriuchi N; Sakamoto J; Mishima H
    Jpn J Clin Oncol; 2011 Jan; 41(1):134-8. PubMed ID: 20819834
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study.
    Hochster HS; Hart LL; Ramanathan RK; Childs BH; Hainsworth JD; Cohn AL; Wong L; Fehrenbacher L; Abubakr Y; Saif MW; Schwartzberg L; Hedrick E
    J Clin Oncol; 2008 Jul; 26(21):3523-9. PubMed ID: 18640933
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Perioperative chemotherapy with or without bevacizumab in patients with metastatic colorectal cancer undergoing liver resection.
    Constantinidou A; Cunningham D; Shurmahi F; Asghar U; Barbachano Y; Khan A; Mudan S; Rao S; Chau I
    Clin Colorectal Cancer; 2013 Mar; 12(1):15-22. PubMed ID: 23021126
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chronomodulated administration of oxaliplatin plus capecitabine (XELOX) as first line chemotherapy in advanced colorectal cancer patients: phase II study.
    Santini D; Vincenzi B; Schiavon G; Di Seri M; Virzí V; Spalletta B; Caricato M; Coppola R; Tonini G
    Cancer Chemother Pharmacol; 2007 Apr; 59(5):613-20. PubMed ID: 16944151
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Our experience of the treatment with XELOX±Bevacizumab for unresectable advanced colorectal cancer].
    Kashiwagi S; Maeda K; Fuyuhiro Y; Nagahara H; Kimura K; Amano R; Noda E; Kubo N; Tanaka H; Muguruma K; Yashiro M; Yamada N; Nakata B; Ohira M; Ishikawa T; Hirakawa K
    Gan To Kagaku Ryoho; 2011 Nov; 38(12):1936-8. PubMed ID: 22202244
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multicenter Phase II study of FOLFOX or biweekly XELOX and Erbitux (cetuximab) as first-line therapy in patients with wild-type KRAS/BRAF metastatic colorectal cancer: The FLEET study.
    Soda H; Maeda H; Hasegawa J; Takahashi T; Hazama S; Fukunaga M; Kono E; Kotaka M; Sakamoto J; Nagata N; Oba K; Mishima H
    BMC Cancer; 2015 Oct; 15():695. PubMed ID: 26467662
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of cytokine-induced killer cell treatment in colorectal cancer patients: a retrospective study.
    Zhang J; Zhu L; Zhang Q; He X; Yin Y; Gu Y; Guo R; Lu K; Liu L; Liu P; Shu Y
    Biomed Pharmacother; 2014 Jul; 68(6):715-20. PubMed ID: 25107840
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of first-line bevacizumab in combination with mFOLFOX6 or XELOX in metastatic colorectal cancer.
    Vedat Bayoglu I; Yildiz I; Varol U; Cokmert S; Kucukzeybek Y; Alacacioglu A; Demir L; Dirican A; Akyol M; Yildiz Y; Oktay Tarhan M
    J BUON; 2015; 20(2):460-7. PubMed ID: 26011336
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cediranib plus FOLFOX/CAPOX versus placebo plus FOLFOX/CAPOX in patients with previously untreated metastatic colorectal cancer: a randomized, double-blind, phase III study (HORIZON II).
    Hoff PM; Hochhaus A; Pestalozzi BC; Tebbutt NC; Li J; Kim TW; Koynov KD; Kurteva G; Pintér T; Cheng Y; van Eyll B; Pike L; Fielding A; Robertson JD; Saunders MP
    J Clin Oncol; 2012 Oct; 30(29):3596-603. PubMed ID: 22965965
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcome of first line systemic treatment in elderly compared to younger patients with metastatic colorectal cancer: a retrospective analysis of the CAIRO and CAIRO2 studies of the Dutch Colorectal Cancer Group (DCCG).
    Venderbosch S; Doornebal J; Teerenstra S; Lemmens W; Punt CJ; Koopman M
    Acta Oncol; 2012 Sep; 51(7):831-9. PubMed ID: 22794910
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic Factors for Colorectal Cancer Patients Treated With Combination of Immune-cell Therapy and First-line Chemotherapy: A Retrospective Study.
    Takimoto R; Kamigaki T; Okada S; Matsuda E; Ibe H; Oguma E; Naitoh K; Makita K; Goto S
    Anticancer Res; 2019 Aug; 39(8):4525-4532. PubMed ID: 31366555
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bevacizumab combined with chemotherapy in the second-line treatment of metastatic colorectal cancer: results from the phase II BEVACOLOR study.
    Bennouna J; Borg C; Delord JP; Husseini F; Trillet-Lenoir V; Faroux R; François E; Ychou M; Goldwasser F; Bouché O; Senellart H; Kraemer S; Douillard JY
    Clin Colorectal Cancer; 2012 Mar; 11(1):38-44. PubMed ID: 21803002
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oxaliplatin-based chemotherapy in patients aged 75 years or older with metastatic colorectal cancer.
    Fukuchi M; Ishibashi K; Tajima Y; Okada N; Yokoyama M; Chika N; Hatano S; Matsuzawa T; Kumamoto K; Kumagai Y; Baba H; Mochiki E; Ishida H
    Anticancer Res; 2013 Oct; 33(10):4627-30. PubMed ID: 24123040
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.